Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.60
+0.14 (1.65%)
At close: Jan 20, 2026, 4:00 PM EST
8.57
-0.03 (-0.32%)
After-hours: Jan 20, 2026, 4:24 PM EST
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$541,818
Profits / Employee
-$1,129,604
Market Cap
748.35M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 192 | 50 | 35.21% | 192 | 0 |
| Dec 31, 2023 | 142 | 9 | 6.77% | 142 | 0 |
| Dec 31, 2022 | 133 | 12 | 9.92% | 133 | 0 |
| Dec 31, 2021 | 121 | 32 | 35.96% | 121 | 0 |
| Dec 31, 2020 | 89 | 29 | 48.33% | 88 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KURA News
- 9 days ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire
- 15 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript - Seeking Alpha
- 6 weeks ago - Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - GlobeNewsWire
- 6 weeks ago - Kura Oncology: A Cautious Buy - Seeking Alpha
- 6 weeks ago - Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data - Seeking Alpha
- 7 weeks ago - First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - GlobeNewsWire